Constellation Pharmaceuticals Investor Presentation — October 2020

Document content

Stellar Science, Breakthrough Medicine

October 29, 2020Developing Next -Generation

Epigenetic Treatments for

Corporate Presentation2

Forward -Looking Statements

This presentation contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of

1995 thatinvolve substantial risks and uncertainties, including statements regarding the implications of preliminary or interim clinical

data, Company’s plans, strategies and prospects for its business and statements regarding the development status of the Company’ s

product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,”

“project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all

forward-looking statements contain these identifying words. Any forward -looking statements are based on management’s current

expectations of future events and are subject toa number of risks and uncertainties that could cause actual results to differ m aterially and

adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but ar e not limited to,

risks associated with the Company’s ability to: obtain and maintain necessary approvals from the FDA and other regulatory author ities;

continue to advance its product candidates in clinical trials; whether preliminary or interim data from a clinical trial will be predictive of the final

results of the trial; replicate in later clinical trials positive results found in preclinical studies and early -stage clinical trials of CPI -0610 and CPI -

0209; advance the development of its product candidates under the timelines it anticipates, or at all, in current and future cli nical trials; obtain,

maintain, or protect intellectual property rights related to its product candidates; manage expenses; raise the substantial addi tional capital

needed to achieve its business objectives; the COVID -19 pandemic and general economic and market conditions. CPI -0610 and CPI -

0209 are investigational therapies and have not been approved by the FDA (or any other regulatory authority). For a discussion of oth er risks

anduncertainties, any of which could cause the Company’s actual results to differ from those contained in the forward -looking statements,

see the “Risk Factors” section, as well as discussions of potential risks, uncertainties, and other important factors, in the Co mpany’s

most recent filings with the Securities and Exchange Commission, including the Company’s Quarterly Report on Form 10 -Q for the quarter